Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|August 25, 2026

The BioPharm Brief: New Approvals and a Rare-Disease Milestone

Listen
0:00 / 0:00

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. It’s a busy day for FDA action, with two approvals and a new designation spanning cancer, autoimmune disease, and rare disease. Here’s what we have today.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.


It’s a busy day for FDA action, with two approvals and a new designation spanning cancer, autoimmune disease, and rare disease. Here’s what we have today.

First, Zymeworks’ Ziihera has won FDA approval for first-line HER2-positive gastroesophageal adenocarcinoma. The approval covers two Ziihera-based regimens for adults with unresectable, locally advanced or metastatic HER2-positive disease. One combines Ziihera with tislelizumab and chemotherapy for HER2-positive tumors regardless of PD-L1 status, while the other combines Ziihera with chemotherapy for HER2 IHC 3+ disease. The decision was supported by Phase 3 HERIZON-GEA-01 data, in which the Ziihera, tislelizumab, and chemotherapy combination reduced the risk of death by 28% compared with trastuzumab plus chemotherapy and produced a median overall survival of 26.4 months. The approval also triggers a $250 million milestone payment to Zymeworks from Jazz Pharmaceuticals.

Next, Johnson & Johnson’s IMAAVY has become the first FDA-approved treatment specifically for warm autoimmune hemolytic anemia. The FcRn-blocking antibody, Imaavy, is approved for adults and patients 12 and older with warm autoimmune hemolytic anemia who are currently or previously treated with corticosteroids. The approval was supported by Phase 2/3 ENERGY data showing durable hemoglobin responses and reduced fatigue compared with placebo. Imaavy works by reducing circulating pathogenic IgG autoantibodies, targeting a key driver of the disease rather than broadly suppressing the immune system.

And Mahzi Therapeutics’ MZ-1866 has received FDA Rare Pediatric Disease Designation for Pitt Hopkins syndrome. The investigational AAV9 gene replacement therapy delivers functional copies of TCF4, the gene underlying the rare neurodevelopmental disorder. The designation comes as Mahzi’s Phase 1/2 UNITE study passes 50% enrollment, with seven of 12 planned participants enrolled. The company says the study is expected to complete enrollment by the end of 2026. If a qualifying therapy ultimately receives approval, the Rare Pediatric Disease designation can make it eligible for a Priority Review Voucher.

That’s The BioPharm Brief for today. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways:

  • Ziihera gains a first-line FDA approval in HER2-positive gastroesophageal cancer.
  • J&J’s IMAAVY becomes the first approved treatment specifically for warm autoimmune hemolytic anemia.
  • Mahzi’s MZ-1866 receives Rare Pediatric Disease Designation as its Pitt Hopkins gene therapy advances through Phase 1/2.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more